JP2025003912A5 - - Google Patents

Info

Publication number
JP2025003912A5
JP2025003912A5 JP2024115829A JP2024115829A JP2025003912A5 JP 2025003912 A5 JP2025003912 A5 JP 2025003912A5 JP 2024115829 A JP2024115829 A JP 2024115829A JP 2024115829 A JP2024115829 A JP 2024115829A JP 2025003912 A5 JP2025003912 A5 JP 2025003912A5
Authority
JP
Japan
Prior art keywords
peptide
car
nanobody
active agent
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024115829A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025003912A (ja
Filing date
Publication date
Priority claimed from PCT/US2019/015290 external-priority patent/WO2019148037A1/en
Application filed filed Critical
Publication of JP2025003912A publication Critical patent/JP2025003912A/ja
Publication of JP2025003912A5 publication Critical patent/JP2025003912A5/ja
Pending legal-status Critical Current

Links

JP2024115829A 2018-01-25 2024-07-19 疾患におけるecmのナノボディに基づく画像化および標的化ならびに開発 Pending JP2025003912A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862621811P 2018-01-25 2018-01-25
US62/621,811 2018-01-25
PCT/US2019/015290 WO2019148037A1 (en) 2018-01-25 2019-01-25 Nanobody based imaging and targeting of ecm in disease and development
JP2020540721A JP7644441B2 (ja) 2018-01-25 2019-01-25 疾患におけるecmのナノボディに基づく画像化および標的化ならびに開発

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020540721A Division JP7644441B2 (ja) 2018-01-25 2019-01-25 疾患におけるecmのナノボディに基づく画像化および標的化ならびに開発

Publications (2)

Publication Number Publication Date
JP2025003912A JP2025003912A (ja) 2025-01-10
JP2025003912A5 true JP2025003912A5 (cg-RX-API-DMAC7.html) 2025-10-15

Family

ID=67299765

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020540721A Active JP7644441B2 (ja) 2018-01-25 2019-01-25 疾患におけるecmのナノボディに基づく画像化および標的化ならびに開発
JP2024115829A Pending JP2025003912A (ja) 2018-01-25 2024-07-19 疾患におけるecmのナノボディに基づく画像化および標的化ならびに開発

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020540721A Active JP7644441B2 (ja) 2018-01-25 2019-01-25 疾患におけるecmのナノボディに基づく画像化および標的化ならびに開発

Country Status (5)

Country Link
US (3) US11597769B2 (cg-RX-API-DMAC7.html)
EP (1) EP3743443A4 (cg-RX-API-DMAC7.html)
JP (2) JP7644441B2 (cg-RX-API-DMAC7.html)
CN (1) CN112218890A (cg-RX-API-DMAC7.html)
WO (1) WO2019148037A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112218890A (zh) 2018-01-25 2021-01-12 麻省理工学院 在疾病和发展中基于纳米抗体的ecm成像和靶向
EP4047016A1 (en) 2021-02-19 2022-08-24 Université de Strasbourg Anti-tenascin-c (tnc) single-domain antibodies (nanobodies) and use thereof
CN113151177B (zh) * 2021-05-21 2023-11-03 四川大学华西医院 乳腺或乳腺癌组织脱细胞基质及其制备方法和用途
US20240238451A1 (en) * 2021-05-28 2024-07-18 Albert Einstein College Of Medicine Single-domain antigen-dependent antibody-like fusion proteins
WO2023179370A1 (en) * 2022-03-21 2023-09-28 The Hong Kong Polytechnic University Peptidic bispecific antibody, methods for preparation and uses thereof
CN117624360A (zh) * 2022-08-26 2024-03-01 南京融捷康生物科技有限公司 一种抗trem2的单域抗体及其用途
AU2023387779A1 (en) * 2022-12-30 2024-08-22 Remegen Co., Ltd. Bispecific antibody and application thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025175132A1 (en) * 2024-02-15 2025-08-21 Board Of Regents, The University Of Texas System Methods for selecting triple-negative breast cancer patients for targeted therapy using tumor-specific total mrna expression

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076456A2 (en) * 1999-06-14 2000-12-21 The General Hospital Corporation Modulators of fibrosis
US9320792B2 (en) * 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
AU2009245724A1 (en) * 2008-05-09 2009-11-12 Ablynx N.V. Amino acid sequences directed against integrins and uses thereof
ES2769574T3 (es) * 2013-03-15 2020-06-26 Michael C Milone Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
EP3455245A2 (en) * 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
WO2018014039A1 (en) * 2016-07-15 2018-01-18 Poseida Therapeutics, Inc. Chimeric antigen receptors (cars) specific for muc1 and methods for their use
CN112218890A (zh) 2018-01-25 2021-01-12 麻省理工学院 在疾病和发展中基于纳米抗体的ecm成像和靶向

Similar Documents

Publication Publication Date Title
JP6906653B2 (ja) 三重特異性結合タンパク質と使用方法
CN104853775B (zh) 针对生长和分化因子15(gdf-15)的单克隆抗体
KR101820029B1 (ko) 암의 예방 및/또는 치료에서 사용하기 위한 방사성 표지 항체 단편
JP2021119138A (ja) 成長分化因子15(gdf−15)に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用
JP2019524745A (ja) Fc結合能力を有する融合タンパク質を含む細胞外小胞
CA2799608C (en) Amino acid sequences which enhance peptide conjugate solubility
TW200825106A (en) Tumor therapy with an anti-VEGF antibody
CN110117329B (zh) 包含趋化因子与结合伴侣的融合多肽及其用途
US11643437B2 (en) Tandem repeat cancer-targeting peptides for molecular conjugation or engineering and uses thereof in cancer theranostics
JP2024056787A (ja) 抗葉酸受容体1抗体及びその使用
JP2014515600A5 (cg-RX-API-DMAC7.html)
CN118302445A (zh) 抗cd155抗体和抗原结合片段及其使用方法
RS58918B1 (sr) Agensi za tretman trostruko negativnog raka dojke
WO2022027828A1 (zh) 用于多特异性抗体递送的纳米适配子及其应用、构建方法
Gunaratne et al. The characterization of variable new antigen receptors targeting FAP isolated from a novel immunized library
US11458208B2 (en) Desmoglein 2 antibody fusion proteins for drug delivery
CN114269779B (zh) 抗bag2抗体和治疗癌症的方法
CN117510642A (zh) 一种全基因编码的双靶向嵌合体及其应用
CN114502781B (zh) 个人化癌症免疫治疗
Gunaratne et al. Development of FAP-targeted theranostics discovered by next-generation sequencing-augmented mining of a novel immunized VNAR library
WO2022242892A1 (en) Anti-cd38 single-domain antibodies in disease monitoring and treatment
CN120058937B (zh) 一种靶向lgr4的纳米抗体nb21及其在抗肥胖治疗中的应用
US20140302050A1 (en) Targeting an amphiregulin-derived cell surface neo-epitope
HK40090440A (en) Anti-folate receptor 1 antibodies and uses thereof
HK40122548A (en) Anti-cd44v6 antibodies and their use to treat cd44v6 overexpressing cancers